Commonwealth Equity Services’s Aimmune Therapeutics AIMT Stock Holding History

Commonwealth Equity Services’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,982	Closed	-$434K	–	3016
2019 Q4	$434K	Buy	12,982 +1,562	+14%	+$43.7K	﹤0.01%	2019
2019 Q3	$239K	Buy	+11,420	New	+$233K	﹤0.01%	2439
2018 Q4	–	Sell	-13,926	Closed	-$379K	–	2859
2018 Q3	$379K	Buy	13,926 +200	+1%	+$5.66K	﹤0.01%	1988
2018 Q2	$369K	Sell	13,726 -143	-1%	-$4.38K	﹤0.01%	1965
2018 Q1	$441K	Sell	13,869 -63	-0.5%	-$2.22K	﹤0.01%	1795
2017 Q4	$527K	Sell	13,932 -9,604	-41%	-$310K	﹤0.01%	1658
2017 Q3	$583K	Sell	23,536 -2,668	-10%	-$57.5K	﹤0.01%	1518
2017 Q2	$539K	Hold	26,204	–	–	﹤0.01%	1524
2017 Q1	$569K	Buy	26,204 +1,348	+5%	+$27.6K	﹤0.01%	1427
2016 Q4	$508K	Buy	+24,856	New	+$508K	﹤0.01%	1400

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Commonwealth Equity Services's AIMT Position: Q1 2020 in Review

Commonwealth Equity Services sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 12,982 shares — an estimated $434K sold.

Commonwealth Equity Services first reported a position in AIMT in Q4 2016 and held it in 10 quarters. The position peaked at $583K in Q3 2017. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

Commonwealth Equity Services reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
Commonwealth Equity Services sold 12,982 Aimmune Therapeutics shares in Q1 2020, an estimated $434K.
Commonwealth Equity Services first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 10 quarters.
Commonwealth Equity Services's Aimmune Therapeutics position peaked at $583K in Q3 2017.
161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Commonwealth Equity Services's 13F filing for Q1 2020, filed 11 May 2020.